These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 22449260

  • 1. Targeting RhoA/ROCK pathway in pulmonary arterial hypertension.
    Antoniu SA.
    Expert Opin Ther Targets; 2012 Apr; 16(4):355-63. PubMed ID: 22449260
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of the RhoA/Rho-associated, coiled-coil-containing protein kinase-1 pathway is involved in the therapeutic effects of simvastatin on pulmonary arterial hypertension.
    Liu WH, Xu XH, Luo Q, Zhang HL, Wang Y, Xi QY, Zhao ZH, Liu ZH.
    Clin Exp Hypertens; 2018 Apr; 40(3):224-230. PubMed ID: 29319354
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats.
    Wang HM, Wang Y, Liu M, Bai Y, Zhang XH, Sun YX, Wang HL.
    Can J Physiol Pharmacol; 2012 Nov; 90(11):1506-15. PubMed ID: 23181278
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.
    Oka M, Fagan KA, Jones PL, McMurtry IF.
    Br J Pharmacol; 2008 Oct; 155(4):444-54. PubMed ID: 18536743
    [Abstract] [Full Text] [Related]

  • 7. Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension.
    Li C, Liu PP, Tang DD, Song R, Zhang YQ, Lei S, Wu SJ.
    Pulm Pharmacol Ther; 2018 Jun; 50():111-122. PubMed ID: 29673911
    [Abstract] [Full Text] [Related]

  • 8. RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension.
    Barman SA, Zhu S, White RE.
    Vasc Health Risk Manag; 2009 Jun; 5():663-71. PubMed ID: 19707285
    [Abstract] [Full Text] [Related]

  • 9. Role of the RhoA/ROCK pathway in high-altitude associated neonatal pulmonary hypertension in lambs.
    Lopez NC, Ebensperger G, Herrera EA, Reyes RV, Calaf G, Cabello G, Moraga FA, Beñaldo FA, Diaz M, Parer JT, Llanos AJ.
    Am J Physiol Regul Integr Comp Physiol; 2016 Jun 01; 310(11):R1053-63. PubMed ID: 26911462
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.
    Raja SG.
    Recent Pat Cardiovasc Drug Discov; 2012 Aug 01; 7(2):100-4. PubMed ID: 22670803
    [Abstract] [Full Text] [Related]

  • 11. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling.
    Guilluy C, Eddahibi S, Agard C, Guignabert C, Izikki M, Tu L, Savale L, Humbert M, Fadel E, Adnot S, Loirand G, Pacaud P.
    Am J Respir Crit Care Med; 2009 Jun 15; 179(12):1151-8. PubMed ID: 19299501
    [Abstract] [Full Text] [Related]

  • 12. Could pharmacological curtailment of the RhoA/Rho-kinase pathway reverse the endothelial barrier dysfunction associated with Ebola virus infection?
    Eisa-Beygi S, Wen XY.
    Antiviral Res; 2015 Feb 15; 114():53-6. PubMed ID: 25512227
    [Abstract] [Full Text] [Related]

  • 13. Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway.
    Xing XQ, Gan Y, Wu SJ, Chen P, Zhou R, Xiang XD.
    Med Hypotheses; 2007 Feb 15; 68(5):1108-13. PubMed ID: 17097823
    [Abstract] [Full Text] [Related]

  • 14. Role of Rho-kinase and its inhibitors in pulmonary hypertension.
    Duong-Quy S, Bei Y, Liu Z, Dinh-Xuan AT.
    Pharmacol Ther; 2013 Mar 15; 137(3):352-64. PubMed ID: 23261521
    [Abstract] [Full Text] [Related]

  • 15. Effects of exercise training and RhoA/ROCK inhibition on plaque in ApoE-/- mice.
    Matsumoto A, Manthey HD, Marsh SA, Fassett RG, de Haan JB, Rolfe BE, Coombes JS.
    Int J Cardiol; 2013 Aug 20; 167(4):1282-8. PubMed ID: 22525349
    [Abstract] [Full Text] [Related]

  • 16. Activation of ERM-family proteins via RhoA-ROCK signaling increases intestinal P-gp expression and leads to attenuation of oral morphine analgesia.
    Kobori T, Harada S, Nakamoto K, Tokuyama S.
    J Pharm Sci; 2013 Mar 20; 102(3):1095-105. PubMed ID: 23303573
    [Abstract] [Full Text] [Related]

  • 17. RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
    Xia Y, Cai X, Fan J, Zhang L, Li Z, Ren J, Wu G, Zhu F.
    Anticancer Drugs; 2017 Jun 20; 28(5):514-521. PubMed ID: 28225457
    [Abstract] [Full Text] [Related]

  • 18. Rho/Rho-associated kinase pathway in glaucoma (Review).
    Wang J, Liu X, Zhong Y.
    Int J Oncol; 2013 Nov 20; 43(5):1357-67. PubMed ID: 24042317
    [Abstract] [Full Text] [Related]

  • 19. Animal models of pulmonary hypertension: Rho kinase inhibition.
    Firth AL, Choi IW, Park WS.
    Prog Biophys Mol Biol; 2012 Aug 20; 109(3):67-75. PubMed ID: 22713173
    [Abstract] [Full Text] [Related]

  • 20. Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE.
    Rozo C, Chinenov Y, Maharaj RK, Gupta S, Leuenberger L, Kirou KA, Bykerk VP, Goodman SM, Salmon JE, Pernis AB.
    Ann Rheum Dis; 2017 Apr 20; 76(4):740-747. PubMed ID: 28283529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.